Statins, namely lovastatin, atorvastatin and simvastatin, exert a therapeutic effect in DSAP by inhibiting the enzyme HMG-CoA reductase, a key component of the mevalonate pathway. The gene discussed is HMGCR; the disease is porokeratosis 3, disseminated superficial actinic type.